跳至主要内容
临床试验/ISRCTN10600261
ISRCTN10600261已完成不适用

A high-calorie challenge within the healthy range of the population

TNO0 个研究点目标入组 100 人开始时间: 2017年5月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100

研究概览

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Healthy male / female subjects (ratio: 50-50), 20 to 70 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, hematology and blood chemistry and the health and lifestyle questionnaire.
  • 2. Body fat percentage within limits of predefined recruitment categories
  • 3. Able to participate and willing to give written informed consent and to comply with the study restrictions

排除标准

  • 1. Participation in an investigational drug or device study within 3 months prior to screening and / or participation of more than 4 times in the previous
  • 2. Loss of blood outside the limits of Sanquin (500 mL) within 3 months prior to screening or not willing to refrain from blood- or plasma donation during the study
  • 3. Average alcohol consumption > 21 units/week for women and > 28 units/week for men
  • 4. Change of smoking habits within two months prior to screening
  • 5. Not having a general practitioner or health insurance
  • 6. Unacceptable concomitant medication use at baseline, e.g., drugs known or likely to interact with the challenge drink or study assessments
  • 7. Use of dietary supplements less than one month prior to Day 1
  • 8. Reported slimming or being on a medically prescribed diet
  • 9. Reported unexplained weight loss or gain of > 2 kg in the last month before screening
  • 10. Reported food allergy or sensitivity for one of the used ingredients
  • 11. Females who are pregnant, planning to be pregnant during the study period, or lactating
  • 12. Not willing to accept information transfer which concerns participation in the study or information regarding health (e.g. laboratory results, findings at
  • health and lifestyle questionnaire, physical examination or eventual adverse events) to and from their general practitioner
  • 13. Having hypertension defined as a systolic blood pressure (SBP) greater than 140 mmHg or diastolic blood pressure (DBP) greater than 90 mmHg
  • (assessed three times at five minutes interval). In the case of isolated systolic hypertension in middle aged volunteers (phenotypic group 5 and 10), the
  • principal investigator will judge whether this condition will cause a clinically significant interference with the study outcome
  • 14. Clinically significant abnormalities, as judged by the Investigator, in laboratory test results. In the case of uncertain or questionable results, tests
  • performed during screening may be repeated once before determination of eligibility
  • 15. Inappropriate veins for cannula insertion
  • 16. Having a chronic disease related to inflammation (such as arthritis)
  • 17. Having a history or symptoms of any significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory,
  • gastrointestinal, hepatic, or renal disorder
  • 18. Any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or
  • alcohol dependence or psychiatric disease
  • 19. Unwillingness or inability to comply with the study protocol for any other reason
  • For the sub investigation (Raman spectroscopy):
  • 20. Dark skin color according to the Fitzpatrick skin type scale (type 5 or 6)
  • 21. Abnormalities of the skin at the desired measurement location (upper side of forearm)

研究者

发起方
TNO

相似试验